Oruka Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
ORKA$109.50+4.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(In thousands)
| Year Ended December 31, 2025 | Period from February 6, 2024 (inception) to December 31, 2024 | |
|---|---|---|
| Net loss | $(105,433) | $(83,724) |
| Other comprehensive income (loss): | ||
| Unrealized gains (losses) on marketable securities | 587 | (41) |
| Total comprehensive loss | $(104,846) | $(83,765) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.